Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Soleno Therapeutics (SLNO) Gross Margin (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Gross Margin for 4 consecutive years, with 99.06% as the latest value for Q4 2025.

  • On a quarterly basis, Gross Margin changed N/A to 99.06% in Q4 2025 year-over-year; TTM through Dec 2025 was 100.48%, a N/A change, with the full-year FY2025 number at 98.58%, changed N/A from a year prior.
  • Gross Margin was 99.06% for Q4 2025 at Soleno Therapeutics, up from 98.27% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 99.06% in Q4 2025 to a low of 98.27% in Q3 2025.